Process development of a potent bradykinin 1 antagonist

…, TD Nelson, MH Kress, DE Frantz

Index: DiMichele, Lisa; Menzel, Karsten; Mills, Paul; Frantz, Doug; Nelson, Todd Magnetic Resonance in Chemistry, 2006 , vol. 44, # 11 p. 1041 - 1043

Full Text: HTML

Citation Number: 25

Abstract

As part of Merck's continued research effort on inflammation and pain, a safe synthesis of an orally bioavailable and CNS penetrant bradykinin 1 antagonist was developed and demonstrated on kilogram scale. The key step included a novel regioselective metal−

Related Articles:

Selective oxidation of 2-bromo-m-xylene to 2-bromo-3-methylbenzoic acid or 2-bromoisophthalic acid

[Bulletin of the Chemical Society of Japan, , vol. 59, p. 3285 - 3286]

Selective oxidation of 2-bromo-m-xylene to 2-bromo-3-methylbenzoic acid or 2-bromoisophthalic acid

[Bulletin of the Chemical Society of Japan, , vol. 59, p. 3285 - 3286]

Selective oxidation of 2-bromo-m-xylene to 2-bromo-3-methylbenzoic acid or 2-bromoisophthalic acid

[Bulletin of the Chemical Society of Japan, , vol. 59, p. 3285 - 3286]

More Articles...